DiaMedica Therapeutics Inc Dossier
Qualitative Analysis
Business overview
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from severe ischemic diseases. The company's primary focus is the development of its lead product candidate, DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1). DM199 is designed to treat acute ischemic stroke (AIS) and preeclampsia (PE) / fetal growth restriction (FGR) by restoring vascular tone, improving blood flow, and enhancing tissue perfusion. DiaMedica operates on a single scientific platform, which concentrates its development efforts but exposes it to high clinical and regulatory binary risks.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the pivotal Phase 2/3 ReMEDy2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of acute ischemic stroke (AIS). The trial reached a 75% enrollment milestone toward its 200-patient interim analysis threshold in May 2026.
Expected impact: A successful trial could establish DM199 as a novel, safe solution to restore vascular health and enhance collateral blood flow in stroke patients.
Developing DM199 as a potential treatment for preeclampsia (PE) and fetal growth restriction (FGR). Following Health Canada clearance in March 2026, the company is preparing to initiate a Phase 2 study in Canada and the United Kingdom, while simultaneously conducting a rat PK study to satisfy U.S. FDA requirements for an IND application.
Expected impact: Addressing a critical unmet medical need with no currently approved therapeutic options in the U.S. or Europe.